Xsolla Partners With iBLOXX to Promote Their Web3 Games Globally and Drive Launch of Upcoming Third-person Shooter Title StrayShot
11.12.2024 10:00:00 CET | Business Wire | Press release
iBLOXX Leverages Xsolla’s Monetization, Marketing, And Distribution Tools To Showcase Games Across MENA
Xsolla, a global video game commerce company, announces a new partnership with iBLOXX, a studio specializing in developing next-generation multiplayer games on the blockchain. The alliance was cultivated at the PGC Dubai event in April 2024, underscoring Xsolla’s continuous commitment to fostering long-term growth within the Middle East and Northern Africa region’s rapidly expanding gaming ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211854266/en/
(Graphic: Xsolla)
This strategic collaboration starts with supporting the launch of their new title, StrayShot. This thrilling third-person shooter game for PC and mobile allows players to step into the boots of a Bounty Hunter, ready to take on rivals in intense matches in several game modes. Players can team up with friends or go solo to fight other players in an epic battle for survival and earn exclusive rewards. This game is unique as it includes Web3 elements, NFTs, and tournaments, all of which Xsolla has solutions to support, particularly when it comes to subscription and virtual currency.
As a pivotal force within the MENA gaming ecosystem, Xsolla continues to leverage its advanced tools and platforms to empower partners and developers. Through this collaboration with iBLOXX, Xsolla is set to elevate the game studio’s reach and performance by providing key monetization, marketing, and distribution capabilities. Xsolla’s payments and monetization technology and expertise will ensure StrayShot gains maximum exposure while optimizing player engagement and revenue generation across multiple channels.
Chris Meredith, SVP EMEA at Xsolla, expressed his enthusiasm about the new partnership, commenting, “It’s great to work with a mature studio in the region with such a long-standing commitment to the growth and development in MENA,” he added. “This partnership will bring their groundbreaking titles and the launch of their newest title, StrayShot, to a wider audience, putting them firmly on the map as a major player in the industry.”
Domenik Maier, CEO of iBLOXX, stated: “We’re thrilled to join forces with Xsolla. Their support will be a game-changer for the upcoming launch of StrayShot, ensuring that it reaches a much larger, more engaged audience!”
The collaboration highlights Xsolla’s unwavering commitment to supporting long-term partnerships that contribute to the sustained growth and innovation of the regional gaming landscape. By partnering with iBLOXX, Xsolla is further enhancing its position in the MENA market, where gaming is experiencing rapid evolution and expansion.
For more information on Xsolla's partnership with iBLOXX to promote Web3 games globally and drive the launch of the upcoming third-person shooter StrayShot, visit xsolla.blog/xipw.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For additional information and to learn more, please visit xsolla.com.
About iBLOXX
iBLOXX is a leading innovator in Web3 gaming, leveraging its extensive background in decentralized technologies and quantitative finance to craft robust, player-driven game economies and deeply engaging virtual worlds. By blending cutting-edge blockchain infrastructure with innovative design principles, iBLOXX aims to deliver richer gaming experiences — where players truly own their in-game assets and game worlds evolve in tandem with their communities.
For additional information about their upcoming title StrayShot, please visit StrayShot.game.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211854266/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom